RGCC announces the launch of Onco-D-clare, a groundbreaking cancer detection test that marks a significant milestone in early cancer screening. Utilizing the cutting-edge technology of molecular biology coupled with artificial neural networks, this innovative test empowers individuals to detect cancer before symptoms manifest.
Onco-D-clare operates by isolating peripheral blood mononuclear cells from blood samples, followed by comprehensive gene expression analysis across more than 90 genes. The expression profile derived from this analysis enables the classification of samples as either cancerous or healthy, providing crucial insights into potential cancer risks.
"Early detection is paramount in the fight against cancer, and Onco-D-clare stands as a beacon of hope in this endeavor. By harnessing the power of gene expression profiling and machine learning algorithms, Onco-D-clare offers personalized insights into each patient's specific cells. With time-efficiency and accuracy, Onco-D-clare marks a pivotal advancement in cancer screening technology, empowering early detection and improving patient outcomes." said Dr. Ioannis Papasotiriou, CEO of RGCC.
By detecting cancer in its early stages, Onco-D-clare equips individuals with essential information to make informed decisions about their future health and well-being.
The Onco-D-clare test can be ordered through the RGCC Doctor’s Portal. Find out more about the test here.